Why FDA approval for Hepcludex changes the treatment landscape for hepatitis delta virus
Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.
Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis
Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.